Aytu BioPharma Inc. (AYTU) Financial Statements (2024 and earlier)

Company Profile

Business Address 7900 E. UNION AVENUE
DENVER, CO 80237
State of Incorp. DE
Fiscal Year End June 30
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
MRQ
12/31/2023
MRQ
6/30/2023
6/30/2022
6/30/2021
6/30/2020
6/30/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments19,52922,98519,36049,64948,08211,044
Cash and cash equivalents19,52922,98519,36049,64948,08211,044
Restricted cash and investments    252252250
Receivables29,40328,93721,71228,1765,1761,741
Inventory, net of allowances, customer advances and progress billings13,00111,99510,84916,3399,9991,440
Inventory13,00111,99510,84916,3399,9991,440
Prepaid expense8,1058,0477,3759,780  
Other current assets1,3338686331,0385,742 
Other undisclosed current assets     5,715958
Total current assets:71,37172,83259,929105,23474,96615,433
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization  159256329 
Operating lease, right-of-use asset2,1332,0543,2713,563634
Property, plant and equipment1,127   259204
Intangible assets, net (including goodwill)55,71158,97070,632151,26649,277221
Goodwill    65,80228,090 
Intangible assets, net (excluding goodwill)55,71158,97070,63285,46421,187221
Deposits noncurrent assets     332
Other noncurrent assets90779276646516,58718,862
Other undisclosed noncurrent assets  1,6562,7694,81111,081 
Total noncurrent assets:59,87863,63177,694160,43477,87119,289
TOTAL ASSETS:131,249136,463137,623265,668152,83634,721
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities53,88646,79948,95276,48919,8493,445
Taxes payable  175 
Employee-related liabilities4,7655,939  
Accounts payable10,473  19,25511,8252,297
Accrued liabilities43,41346,79944,18751,2957,8501,148
Deferred revenue     339
Debt1,0651,6489616,668982 
Derivative instruments and hedges, liabilities      
Business combination, contingent consideration, liability    4,0557131,078
Other liabilities9,2367,0905,359 840 
Other undisclosed current liabilities  13,47810,03512,2265,583849
Total current liabilities:64,18769,01564,442109,43828,3075,373
Noncurrent Liabilities
Long-term debt and lease obligation, including: 14,97814,71314,27918011,897 
Long-term debt, excluding current maturities 14,978   11,171 
Finance lease, liability   84180 
Other undisclosed long-term debt and lease obligation  14,71312,105(2,624)  
Liabilities, other than long-term debt19,23113,37812,8108,35717,61822,261
Other liabilities6,3446,97512,8103554,732 
Operating lease, liability   2,0902,624725
Business combination, contingent consideration, liability    8,00212,87422,248
Derivative instruments and hedges, liabilities12,8876,403  1113
Other undisclosed noncurrent liabilities    10,125  
Total noncurrent liabilities:34,20928,09127,08918,66229,51422,261
Total liabilities:98,39697,10691,531128,10057,82127,634
Equity
Equity, attributable to parent32,85339,35746,092137,56895,0157,088
Preferred stock      0
Common stock1143132
Additional paid in capital345,321343,485334,560315,864215,013113,475
Accumulated deficit(312,469)(304,129)(288,472)(178,299)(120,010)(106,390)
Total equity:32,85339,35746,092137,56895,0157,088
TOTAL LIABILITIES AND EQUITY:131,249136,463137,623265,668152,83634,721

Income Statement (P&L) ($ in thousands)

3/31/2024
TTM
12/31/2023
TTM
6/30/2023
6/30/2022
6/30/2021
6/30/2020
6/30/2019
Revenues98,498107,39996,66965,63227,6327,320
Cost of revenue(36,204)(40,767)(44,386)(36,432)(7,553)(2,202)
Cost of goods and services sold(14,046)(40,767)(2,186)(7,332)  
Gross profit:62,29466,63252,28329,20020,0795,118
Operating expenses(69,823)(83,697)(163,844)(88,070)(48,763)(24,167)
Other undisclosed operating income     7,5532,202
Operating loss:(7,529)(17,065)(111,561)(58,870)(21,131)(16,847)
Nonoperating income (expense)(9,063)141,2788407,510(10,285)
Other nonoperating income (expense)(4,355)(4,779)(862)(2,050) 81
Interest and debt expense(5)(9)(14)(1,569)(316)(536)
Loss from continuing operations before equity method investments, income taxes:(16,597)(17,060)(110,297)(59,599)(13,936)(27,667)
Other undisclosed income (loss) from continuing operations before income taxes(572)9141,569  
Loss from continuing operations before income taxes:(17,169)(17,051)(110,283)(58,030)(13,936)(27,667)
Income tax expense (benefit)(828) 110(259)  
Loss from continuing operations:(17,997)(17,051)(110,173)(58,289)(13,936)(27,667)
Loss before gain (loss) on sale of properties:(110,173)(58,289)(13,936)(27,667)
Net loss:(17,997)(17,051)(110,173)(58,289)(13,936)(27,667)
Other undisclosed net income attributable to parent     316536
Net loss available to common stockholders, diluted:(17,997)(17,051)(110,173)(58,289)(13,621)(27,132)

Comprehensive Income ($ in thousands)

3/31/2024
TTM
12/31/2023
TTM
6/30/2023
6/30/2022
6/30/2021
6/30/2020
6/30/2019
Net loss:(17,997)(17,051)(110,173)(58,289)(13,936)(27,667)
Comprehensive loss, net of tax, attributable to parent:(17,997)(17,051)(110,173)(58,289)(13,936)(27,667)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: